EP3373958A4 - Proteasome modulation for treatment of corneal disorders - Google Patents

Proteasome modulation for treatment of corneal disorders Download PDF

Info

Publication number
EP3373958A4
EP3373958A4 EP16865148.7A EP16865148A EP3373958A4 EP 3373958 A4 EP3373958 A4 EP 3373958A4 EP 16865148 A EP16865148 A EP 16865148A EP 3373958 A4 EP3373958 A4 EP 3373958A4
Authority
EP
European Patent Office
Prior art keywords
treatment
corneal disorders
proteasome modulation
proteasome
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16865148.7A
Other languages
German (de)
French (fr)
Other versions
EP3373958A1 (en
Inventor
Fawzia BARDAG-GORCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Ucla Medical Center
Original Assignee
Harbor Ucla Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Ucla Medical Center filed Critical Harbor Ucla Medical Center
Publication of EP3373958A1 publication Critical patent/EP3373958A1/en
Publication of EP3373958A4 publication Critical patent/EP3373958A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16865148.7A 2015-11-13 2016-11-11 Proteasome modulation for treatment of corneal disorders Withdrawn EP3373958A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562255338P 2015-11-13 2015-11-13
PCT/US2016/061656 WO2017083741A1 (en) 2015-11-13 2016-11-11 Proteasome modulation for treatment of corneal disorders

Publications (2)

Publication Number Publication Date
EP3373958A1 EP3373958A1 (en) 2018-09-19
EP3373958A4 true EP3373958A4 (en) 2019-05-22

Family

ID=58695496

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16865148.7A Withdrawn EP3373958A4 (en) 2015-11-13 2016-11-11 Proteasome modulation for treatment of corneal disorders

Country Status (7)

Country Link
US (1) US10736934B2 (en)
EP (1) EP3373958A4 (en)
JP (1) JP2018533590A (en)
KR (1) KR20180080310A (en)
CN (1) CN108430496A (en)
AU (1) AU2016353333A1 (en)
WO (1) WO2017083741A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086986A1 (en) 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
AU2003291356A1 (en) * 2002-11-06 2004-06-03 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
EA008496B1 (en) * 2002-12-20 2007-06-29 Чакшу Рисерч, Инк. Ophthalmic formulation for the prevention and treatment of ocular conditions
US9993558B2 (en) * 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
JP2009500297A (en) * 2005-06-08 2009-01-08 セントカー・インコーポレーテツド Cell therapy for ocular degeneration
CN103619327A (en) * 2010-12-29 2014-03-05 嘉德治疗股份有限公司 Ocular drug delivery system

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARDAG-GORCE F ET AL: "Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease", EXPERIMENTAL AND MOLECULAR PATHOLOGY, ACADEMIC PRESS, US, vol. 90, no. 1, 29 October 2009 (2009-10-29), pages 123 - 130, XP027582145, ISSN: 0014-4800, [retrieved on 20101029] *
CHOI SEUNG-IL ET AL: "Autophagy is induced by raptor degradation via the ubiquitin/proteasome system in granular corneal dystrophy type 2", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 450, no. 4, 17 July 2014 (2014-07-17), pages 1505 - 1511, XP029044918, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2014.07.035 *
ESTEY ET AL: "ALDH3A1: a corneal crystallin with diverse functions", EXPERIMENTAL EYE RESEA, ACADEMIC PRESS LTD, LONDON, vol. 84, no. 1, 25 November 2006 (2006-11-25), pages 3 - 12, XP005727360, ISSN: 0014-4835, DOI: 10.1016/J.EXER.2006.04.010 *
EUI SEOK HAN ET AL: "Long-term outcome and prognostic factor analysis for keratolimbal allografts", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY ; INCORPORATING GERMAN JOURNAL OF OPHTHALMOLOGY, SPRINGER, BERLIN, DE, vol. 249, no. 11, 12 August 2011 (2011-08-12), pages 1697 - 1704, XP019968688, ISSN: 1435-702X, DOI: 10.1007/S00417-011-1760-3 *
KLINGENSTEIN ET AL: "Decrease in Bilateral Corneal Deposits After Bortezomib/ Dexamethasone Chemotherapy in Monoclonal Gammopathy: Case Report", JOURNAL OF ANALYTICAL ONCOLOGY, vol. 1, 25 June 2012 (2012-06-25), pages 103 - 106, XP055579685, DOI: 10.6000/1927-7229.2012.01.01.15 *
See also references of WO2017083741A1 *
SHENG-MIN HSU ET AL: "Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis", MEDIATORS OF INFLAMMATION., vol. 2015, 7 September 2014 (2014-09-07), GB, pages 1 - 10, XP055580096, ISSN: 0962-9351, DOI: 10.1155/2015/847373 *

Also Published As

Publication number Publication date
US10736934B2 (en) 2020-08-11
WO2017083741A1 (en) 2017-05-18
KR20180080310A (en) 2018-07-11
CN108430496A (en) 2018-08-21
US20180369316A1 (en) 2018-12-27
EP3373958A1 (en) 2018-09-19
AU2016353333A1 (en) 2018-06-21
JP2018533590A (en) 2018-11-15

Similar Documents

Publication Publication Date Title
HK1231417A1 (en) Compounds for treating ophthalmic diseases and disorders
EP3212233A4 (en) Combination therapy for treatment of disease
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3110417A4 (en) Amino compounds for treatment of complement mediated disorders
EP3122878A4 (en) Mrna therapy for the treatment of ocular diseases
EP3185876A4 (en) Compositions and methods for treatment of neurological disorders
EP3157463A4 (en) Methods and devices for treating posterior ocular disorders
EP3240612A4 (en) Methods of treating retinal diseases
EP3374502A4 (en) Methods for the treatment of corneal dystrophies
EP3137481A4 (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
EP3191185A4 (en) Device for targeted treatment of dermastoses
EP3215148A4 (en) Methods for treatment of cognitive decline
RS61504B1 (en) Heteroaryl compounds for the treatment of ophthalmic diseases
EP3209732A4 (en) Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
EP3554505A4 (en) Methods of treating ocular disorders
EP3340974A4 (en) Methods for treatment of diseases
IL258593A (en) Compounds for treatment of hypoproliferative disorders
EP3370709A4 (en) Use of proteasome inhibitors to treat ocular disorders
EP3213762A4 (en) Novel treatment of cornea using laminin
EP3209295A4 (en) Methods of treating ocular conditions
EP3302382A4 (en) Implant for treatment of an ocular condition
IL259381B (en) Mirabegron for the treatment of retinal diseases
PT3407879T (en) Ophthalmic gabapentin for the treatment of corneal ulcers
EP3229908A4 (en) Gdnf induction for the treatment of retinal disorders
EP3271017A4 (en) Treatment of skin conditions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190423

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/55 20060101AFI20190415BHEP

Ipc: A61P 27/02 20060101ALI20190415BHEP

Ipc: A61K 31/00 20060101ALI20190415BHEP

Ipc: A61K 38/16 20060101ALI20190415BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20200821